Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on January 5, 2005, to report on the expiration of previous Change-in-Control Agreements and the entry into new agreements with Named Executive Officers and other key executives, effective January 1, 2005. These new agreements are materially similar to the expired ones and are designed to provide financial and other benefits to executives in the event of a change in control of the company followed by their termination within 36 months. This filing indicates a proactive approach by the company to retain and incentivize its executive team during a potentially uncertain period, offering a level of security that could influence executive decision-making and stability.
Key Highlights
- 1New Change-in-Control Agreements were entered into on January 1, 2005, replacing expired agreements.
- 2The new agreements are for a term of one year, automatically renewing annually unless notice of termination is given.
- 3Benefits are triggered by a 'change in control' event followed by involuntary termination (not for cause) or voluntary termination for 'good reason' within 36 months.
- 4'Change in control' is broadly defined to include significant stock ownership changes (20% threshold), mergers/consolidations not preserving existing ownership, asset sales, or director replacement.
- 5Severance includes a lump sum payment of three times base salary plus bonus, earned incentive compensation, and pro-rata current year compensation.
- 6Executives receive accelerated vesting of stock options, lapse of restrictions on restricted stock, and enhanced retirement benefits (36 additional months of service/age credit).
- 7Continued life, health insurance, perquisites for 36 months post-termination, and eligibility for retiree medical/dental plans are provided.
- 8The company will gross-up excise taxes on 'excess parachute payments' or reduce payments if a 10% reduction avoids the tax.
- 9Executives must sign non-compete, non-solicitation, and general release agreements to receive these benefits.
Frequently Asked Questions
The primary purpose of these new agreements is to provide financial and other benefits to key executives in the event of a 'change in control' of Bristol-Myers Squibb, coupled with a subsequent termination of their employment. This aims to secure executive retention and align their interests with shareholders during potential transition periods.
Executives are entitled to a significant severance package, including a lump sum payment equal to three times their base salary plus bonus, accelerated vesting of stock options, enhanced retirement benefits, continued health and life insurance for 36 months, and other perquisites. The specific details of retirement benefits are enhanced to reflect 36 additional months of service and age.
A 'change in control' is defined by several events, including any person acquiring beneficial ownership of 20% or more of the company's common stock, the consummation of a merger or consolidation where existing shareholders do not retain at least 75% of voting power, approval of a plan of liquidation or sale of substantially all assets, or replacement of a majority of the board of directors within a two-year period.
Yes, executives must be terminated either involuntarily and not for 'Cause,' or voluntarily for 'Good Reason,' within 36 months following a 'change in control.' Additionally, to receive the benefits, executives are required to sign a non-compete, non-solicitation, and general release agreement.